Citius Oncology Partners with Er-Kim to Broaden LYMPHIR Distribution in Turkey and the Middle East
Citius Oncology, Inc., a subsidiary focused on oncology within Citius Pharmaceuticals, has taken a significant step toward enhancing its global reach by entering into a distribution agreement with Turkey's Er-Kim İlaç Sanayi ve Ticaret A.Ş. This collaboration marks the expansion of Citius Oncology's innovative cancer treatment, LYMPHIR (denileukin diftitox-cxdl), across Turkey and various Gulf Cooperation Council (GCC) nations, which include Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE.
LYMPHIR is a unique immunotherapy approved by the U.S. FDA for adult patients suffering from relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following prior systemic therapy. The agreement with Er-Kim sees the latter being exclusively responsible for the distribution, sales, marketing, and reimbursement activities concerning LYMPHIR in these regions under the stipulations of local regulations. This partnership allows Citius Oncology to leverage Er-Kim's established network and expertise in navigating complex pharmaceutical landscapes, which is particularly crucial for the distribution of oncology products.
Current access for LYMPHIR extends to 19 markets outside the United States. Most recently, Citius Oncology announced its entrance into several European markets, including Greece, Cyprus, and Bulgaria. The strategic distribution partnership with Er-Kim is essential for Citius Oncology’s mission to improve access to effective oncology treatment options for patients suffering from challenging cancer conditions.
“This agreement is a pivotal moment in our global expansion strategy,” remarked Leonard Mazur, Chairman and CEO of Citius Oncology. Mazur expressed confidence in Er-Kim's experience and success in providing vital oncology therapies to patients across international markets. With Er-Kim's well-established regulatory capabilities coupled with their commitment to improving patient access, Citius Oncology anticipates profound positive impacts on the oncology community in Turkey and the GCC region.
Er-Kim's responsibilities within this partnership include all aspects of product promotion and managing relationships with healthcare professionals to facilitate sales and reimbursement processes. Citius Oncology will ensure a consistent supply of finished product to support these activities, reinforcing its dedication to providing healthcare solutions where they are most needed.
LYMPHIR is recognized as a promising alternative in managing cutaneous T-cell lymphoma, a cancer characterized by skin lesions due to the abnormal proliferation of T-cells. Patients with this condition often deal with significant challenges in managing their symptoms, primarily characterized by painful skin lesions. As a groundbreaking immunotherapy, LYMPHIR functions by targeting and depleting subsets of lymphocytes that contribute to the proliferation and survival of the cancerous T-cells.
With the burgeoning number of patients diagnosed with CTCL, the demand for effective therapies is increasing; thus, Citius Oncology's market estimates suggest that LYMPHIR's initial market potential could exceed $400 million. The company remains committed to developing and commercializing unique oncology therapies, navigating the regulatory landscapes necessary for launching critically needed treatments in underserved markets. In addition to LYMPHIR, Citius Oncology is working on developing other pivotal oncology treatments that address significant medical gaps.
Citius Oncology continues to operate with a vision to forge impactful collaborations that enhance patient access to innovative therapies globally. By partnering with Er-Kim, the company is well-positioned to ensure that patients in Turkey and throughout the Middle East can successfully access and benefit from LYMPHIR's advanced therapeutic capabilities.
As Citius Oncology broadens its distribution networks and engages with strategic partners worldwide, it demonstrates unwavering commitment to supporting healthcare providers and patients in their fight against complex and challenging cancers. The partnership with Er-Kim is just one of many steps the company is taking towards fulfilling its mission to change the landscape of cancer treatment worldwide.
LYMPHIR is a unique immunotherapy approved by the U.S. FDA for adult patients suffering from relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following prior systemic therapy. The agreement with Er-Kim sees the latter being exclusively responsible for the distribution, sales, marketing, and reimbursement activities concerning LYMPHIR in these regions under the stipulations of local regulations. This partnership allows Citius Oncology to leverage Er-Kim's established network and expertise in navigating complex pharmaceutical landscapes, which is particularly crucial for the distribution of oncology products.
Current access for LYMPHIR extends to 19 markets outside the United States. Most recently, Citius Oncology announced its entrance into several European markets, including Greece, Cyprus, and Bulgaria. The strategic distribution partnership with Er-Kim is essential for Citius Oncology’s mission to improve access to effective oncology treatment options for patients suffering from challenging cancer conditions.
“This agreement is a pivotal moment in our global expansion strategy,” remarked Leonard Mazur, Chairman and CEO of Citius Oncology. Mazur expressed confidence in Er-Kim's experience and success in providing vital oncology therapies to patients across international markets. With Er-Kim's well-established regulatory capabilities coupled with their commitment to improving patient access, Citius Oncology anticipates profound positive impacts on the oncology community in Turkey and the GCC region.
Er-Kim's responsibilities within this partnership include all aspects of product promotion and managing relationships with healthcare professionals to facilitate sales and reimbursement processes. Citius Oncology will ensure a consistent supply of finished product to support these activities, reinforcing its dedication to providing healthcare solutions where they are most needed.
LYMPHIR is recognized as a promising alternative in managing cutaneous T-cell lymphoma, a cancer characterized by skin lesions due to the abnormal proliferation of T-cells. Patients with this condition often deal with significant challenges in managing their symptoms, primarily characterized by painful skin lesions. As a groundbreaking immunotherapy, LYMPHIR functions by targeting and depleting subsets of lymphocytes that contribute to the proliferation and survival of the cancerous T-cells.
With the burgeoning number of patients diagnosed with CTCL, the demand for effective therapies is increasing; thus, Citius Oncology's market estimates suggest that LYMPHIR's initial market potential could exceed $400 million. The company remains committed to developing and commercializing unique oncology therapies, navigating the regulatory landscapes necessary for launching critically needed treatments in underserved markets. In addition to LYMPHIR, Citius Oncology is working on developing other pivotal oncology treatments that address significant medical gaps.
Citius Oncology continues to operate with a vision to forge impactful collaborations that enhance patient access to innovative therapies globally. By partnering with Er-Kim, the company is well-positioned to ensure that patients in Turkey and throughout the Middle East can successfully access and benefit from LYMPHIR's advanced therapeutic capabilities.
As Citius Oncology broadens its distribution networks and engages with strategic partners worldwide, it demonstrates unwavering commitment to supporting healthcare providers and patients in their fight against complex and challenging cancers. The partnership with Er-Kim is just one of many steps the company is taking towards fulfilling its mission to change the landscape of cancer treatment worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.